A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

NCT02407054 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer Metastatic

Interventions

DRUG: LY3023414
DRUG: Enzalutamide
DRUG: Placebo

Sponsor

Eli Lilly and Company

Collaborators

[object Object]